BioTech Social Media and Updates

EMP‑01 Shows Strong Patient‑Reported Gains in Social Anxiety

What incredible news to wake up to! Some weeks ago, @ataibeckley reported positive topline results for EMP-01 (oral R-MDMA, a patent-protected version of #MDMA) for Social Anxiety Disorder(SAD). The data reported was the reduction in symptoms as reported by the treating clinician. More importantly, what truly matters is how patients feel - and, even more so, how their real-world behavior changes. Today, $ATAI released the expanded Phase 2a results for EMP-01 including patient-reported assessment and real-world behavioral outcomes - and the additional data is imo spectacular. At Day 43, EMP‑01 achieved: · a 38% reduction vs 15% on placebo (Hedges’ g=0.84) on the patient-reported Social Phobia Inventory (SPIN), · a 32% reduction vs 14% on placebo on the Subtle Avoidance Frequency Examination (SAFE), and · a previously reported −11.9-point LS mean difference (LSMD) on the Liebowitz Social Anxiety Scale (LSAS) versus placebo (g=0.45) All of that with 49% responder rates on both Clinical Global Impression-Improvement (CGI-I) (previously reported) and Patient Global Impressions of Change (PGI-C). And all of that with NO severe or serious adverse events. This milestone imo is highly significant for both patients and investors. There are very few innovative medicines on the horizon that meaningfully address SAD - a vast and underserved market. Estimates suggest that approximately 5–10% of people worldwide will experience social anxiety disorder at some point in their lives. Let that sink in. The current standard of care largely relies on benzodiazepines. However, benzos do not make people more social - they simply numb fear and anxiety. They are not a solution, and they come with well-known dependency risks and other serious side effects. The unmet need remains enormous. Beyond Social Anxiety Disorder, the exploratory trial suggests that EMP-01 may possess a differentiated and clinically compelling pharmacodynamic profile. In simplified terms, its observed effects appear to combine prosocial, affect-enhancing properties of MDMA with the perceptual and insight-oriented qualities associated with psilocybin. This potentially hybrid profile could be highly relevant across a broader range of neuropsychiatric indications characterized by maladaptive emotional processing and impaired social cognition, including PTSD, adjustment disorder, and related stress- and trauma-related conditions. All of that is especially valuable in the light of the strong clinical evidence racemic MDMA has already generated across a range of mental health indications. However, racemic MDMA is essentially generic, making meaningful patent protection extremely difficult – which is at least one reason why MDMA hasn’t made it into the medical world yet. And maybe never will. ATAI having robust patent protection on R-MDMA and now generating such strong and compelling data for its first indication makes imo EMP-01 the 3rd potential superstar in AtaiBeckley’s portfolio next to BPL-003 and VLS-01. Please find the full news here: https://t.co/DXCOD845t9